World Sickle Cell Day is observed on 19 June every year to promote public awareness regarding sickle cell disease and its treatment methods. Sickle cell disease (SCD) is an inherited genetic abnormality of haemoglobin. This causes stuck in small blood vessels, which can decrease blood flow and oxygen to parts of the body. Normally, red blood cells are round that can move easily through the blood vessels. In sickle cell anemia, the red blood cells become rigid and sticky. Red blood cells can live up to 120 days before the body needs to replace them, while sickle cells last only 10 to 20 days causing anaemia because of red blood cells disorder.
- How Robots Are Introducing A New Dimension To Healthcare Service Delivery
- Global Top Players in Intraocular Lens (IOL) Market
- Analyzing the Most Promising Drugs That Will Lose Patent in the US & EU in 2022
- Wearable Technology in Healthcare: Major Benefits and Trends
- World Population Day 2018
- How Metaverse is Set to Transform the Healthcare Dynamics?
World Sickle Cell Day
Jun 19, 2019 | Reading Time: < 1 minute
AstraZeneca’s Imfinzi for Biliary Tract Cancer; FDA Clears Boehringer’s Spesolimab; Novo Nordisk to Acquire Forma Therapeutics; Sanofi’s Xenpozyme Approved for ASMD; Another FDA Approval to Azurity’s Konvomep; Amgen’s Lumakras Trial Results; FDA Grants Priority Review to Sanofi & Sobi’s efanesoctocog alfa; Neurocrine Bio to Takeover UK Biotech Diurnal
FDA Approves AstraZeneca’s Imfinzi for Biliary Tract Cancer Imfinzi, a checkpoint inhibitor developed by AstraZeneca, has been approved by the FDA as the first immunotherapy for biliary tract cancer (BTC), a rare and aggressive form of cancer with few treatment options. Imfinzi (durvalumab) has been approved by ...Find More
FDA Approves AstraZeneca’s Enhertu; Bayer Wins FDA Approval for Prostate Cancer Therapy, Nubeqa; Gilead Sciences to Acquire MiroBio; AstraZeneca & Merck’s Lynparza Gets EU Approval; Pfizer to Acquire Global Blood Therapeutics; Sironax Raises USD 200 Million
FDA Approves AstraZeneca’s Enhertu as First Targeted Therapy for HER2-low Cancer Enhertu, developed by AstraZeneca and Daiichi Sankyo, has been approved by the FDA as the first targeted therapy for HER2-low breast cancer, a new subtype of the disease previously categorized as HER2-negative. It has the potential ...Find More
Immunocore’s Kimmtrak; Samsung Acquires Biogen’s Biosimilar Unit; Novavax’s COVID-19 Vaccine; CHMP Approves Dupixent (dupilumab); Glenmark’s High Blood Pressure Treatment; Roche’s Faricimab; GBT’s Voxelotor
Immunocore Receives FDA Approval for the First Uveal Melanoma Treatment, As Well As the First T-cell Receptor Therapeutics Uveal Melanoma, an aggressive eye cancer, has proven to be a tough nut to crack for researchers seeking a cure. However, with the approval of a new treatment, those with the disorder will ha...Find More
Sign Up & Stay Informed
Penetrative insights and rich analysis of Pharma, Biotech and MedTech space.Join Up Now!
Sign up For Newsletters
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
ASCO Conference 2022
The American Society of Clinical Oncology is a platform that provides a global connection to researchers, pharma companies, and healthcare professions standing against cancer, finding a cure for it.